Levitte Labs announce an LOI for the acquisition of 3 more pharmacies specializing in addiction.
Exploring the companies and themes that make up this emerging and exciting new sector
Psilocybin therapy boosts cognitive and neural flexibility in depressed patients, study finds
Psilocybin-assisted psychotherapy appears to increase both cognitive and neural flexibility in patients with major depressive disorder, according to new research published in Translational Psychiatry.
Numinus to Host Extension of MAPS-Sponsored MDMA-Assisted Therapy for PTSD Trials
Numinus' Montreal and Vancouver clinics will be host for an extension of the MAPS Phase III clinical trial on MDMA-assisted therapy for PTSD.
COMPASS Pathways announces positive topline results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression
Compass Pathways reports successful results from its Phase IIb clinical trial of COMP360 for the treatment of Treatment Resistant Depression (TRD).
MINDCURE Positioned For Strong Run In 2022 – CEO Q&A
MINDCURE's President and CEO, Kelsey Ramsden updates investors on iSTRYM's launch and rapid penetration, as well as drug development news on several fronts.
Cybin Announces Positive CYB003 Data Demonstrating Significant Advantages Over Oral Psilocybin for Treatment of Mental Health
CYB003 is demonstrating superior treatment properties vs. an oral dosage of psilocybin.
Novamind Reports FY2021 Financial Results and Operating Highlights
Novamind reports its full year results for fiscal 2021, including industry-leading revenue of CAD$6 million.
MINDCURE’s Update Hints At Big Things To Come
As MINDCURE's iSTRYM digital therapeutics platform rapidly gathers momentum, the company looks poised to join the emerging rally in the sector.
MINDCURE Provides Update on Studies and Clinical Trials
Mind Cure Health Inc., is pleased to provide an operational progress update on the strategic initiatives of its operating segments - MINDCURE Research and MINDCURE Technology.
Cybin Granted DEA Schedule I Manufacturing License
Cybin announces receiving its DEA Schedule I Manufacting License, necessary to work with Schedule I controlled substances in the U.S.
Bright Minds Biosciences Commences Trading on the Nasdaq Under the Ticker Symbol "DRUG"
Bright Minds Biosciences announces it has uplisted to the NASDAQ, trading under the symbol "DRUG".
Wonderland: Miami Takes Shape as the Largest Psychedelic Medicine Business Event
On November 8 and 9, Miami, Florida will host Wonderland: Miami, the largest-ever business gathering in the psychedelic medicine sector, presented by Microdose, a guide to the business of psychedelics. Wonderland: Miami will be held at the Adrienne Arsht Center for the Performing Arts in Downtown Miami, Florida.